United States specialty pharmaceutical companies build their launch machinery against a framework the FDA has spent four decades refining. Direct-to-consumer television, a speaker bureau, a sampling program, an unbranded disease-awareness site, a patient-influencer partnership: each occupies a settled position in 21 C.F.R. § 202.1 and in the guidance that has grown around it. Moved to Switzerland and the European Union, that machinery does not simply require recalibration. Several of its components are unlawful on arrival, and the provisions that make them unlawful are not the ones a US compliance file was built to satisfy.
1. Where the Line Falls Between Public and Professional Promotion
Direct-to-consumer advertising of prescription medicines is lawful in the United States, and the statutory hook is misbranding. An advertisement that omits the required risk information renders the drug misbranded under 21 U.S.C. § 352(n), and the implementing regulation supplies the brief summary and the fair-balance requirement. A broadcast advertisement must include a major statement of the product's major side effects and contraindications, and must contain the brief summary unless adequate provision is made for disseminating the approved product labeling; the requirement that the major statement be presented in a clear, conspicuous and neutral manner in television and radio advertisements presented directly to consumers has been in effect since 25 March 2008, and the standards by which that presentation is measured carry a compliance date of 20 November 2024.1US prescription-drug advertising: 21 U.S.C. 352(n) and 21 C.F.R. 202.1, with the 2023 clear, conspicuous and neutral final rule. The US rules rest on disclosure. Say enough about risk, and the message may run.
European law does not offer that trade. Art. 88(1)(a) of Directive 2001/83/EC requires Member States to prohibit advertising to the general public of medicines available only on prescription, and no quantity of disclosure cures the prohibition.2Directive 2001/83/EC, Title VIII and Title VIIIa, the Union advertising regime for medicinal products. Switzerland reaches the same destination by a different road. Art. 31 HMG permits advertising for all types of medicines only where it is directed exclusively at the persons who prescribe or dispense them, and permits public advertising only for medicines that are not subject to prescription; Art. 32 HMG then makes public advertising of prescription-only medicines unlawful outright.3Heilmittelgesetz (HMG, SR 812.21), the Swiss federal statute governing therapeutic products, advertising and integrity. The AWV narrows the aperture further, opening public advertising only to the dispensing categories the ordinance names and to cantonally authorized medicines, and then only where no other statutory provision restricts or forbids it.4Arzneimittel-Werbeverordnung (AWV, SR 812.212.5), the Swiss ordinance on the advertising of medicinal products.
A US reader will translate this as a question about audience, and will ask which recipients a message reaches. Swiss law asks a prior question, and asks it about the product rather than the audience: whether the medicine may lawfully be promoted at all. Art. 32 HMG makes advertising unlawful for medicines that may not be placed on the market, nationally or cantonally. A centralized European authorization is not a Swiss authorization. A molecule that may be promoted to prescribers across the Union remains un-advertisable in Switzerland until Swissmedic has authorized it, and once authorized, the promotional claims must track the product information that Swissmedic approved rather than the summary of product characteristics the European Medicines Agency approved.
The obvious response, that a sponsor can situate its European promotional activity in whichever Member State reads the Directive most generously, assumes that the Directive leaves room. It does not. In Gintec the Court of Justice held that Directive 2001/83/EC brought about complete harmonization in the field of the advertising of medicinal products, the cases in which Member States are authorized to depart from it being expressly listed.5Case C-374/05, holding that the Directive completely harmonizes the advertising of medicinal products. Art. 87(2) of the Directive requires all parts of the advertising of a medicinal product to comply with the summary of product characteristics, and, for advertising directed at prescribers, the Court has held that supplementary claims are permissible only where they confirm or clarify that summary in a manner compatible with it, without distorting it, and only where they are also consistent with Art. 87(3) and Art. 92(2) and (3) Directive 2001/83/EC.6Case C-249/09, on quotations from medical journals and claims that supplement the summary of product characteristics. Teams accustomed to the American separation between promotional speech and scientific exchange will recognize the difficulty at once: the European rule does not turn on which internal function delivered the message.
There is a further trap in the Swiss text, and it is a citation trap. Art. 33 HMG, the provision that once carried the prohibition on promising and accepting pecuniary advantages, was repealed with effect from 1 January 2020. The integrity rule has sat in Art. 55 HMG since 1 January 2020, and its detail sits in a separate ordinance.3 A compliance memorandum that still cites Art. 33 HMG is citing a provision that no longer exists, and the substance did not disappear when the number did. It moved, and it grew teeth.
2. Disease Awareness and the Reference That Cannot Even Be Indirect
Help-seeking communications fall outside the American definition of an advertisement because they neither name a product nor make a representation about one. The FDA's draft guidance on help-seeking and other disease-awareness communications was issued in January 2004, never finalized, and withdrawn in May 2015; the principle rests on the statutory definitions rather than on any guidance in force.1 The test a US team applies is close to mechanical. Was the product named?
Art. 86 of the Directive removes from the advertising regime "information relating to human health or diseases, provided that there is no reference, even indirect, to medicinal products."2 Everything turns on the word "indirect." The Swiss formulation is the same in substance: the AWV excludes general information about health or diseases only where that information refers neither directly nor indirectly to particular medicines.4 Neither instrument asks whether the product was named.
Three judgments show how far the concept reaches. In Damgaard, the Court held that the dissemination of information about a medicinal product by a third party may constitute advertising even where that third party acts on his own initiative and completely independently, in law and in fact, of the manufacturer and the seller; what determines the characterization is the aim of the message.7Case C-421/07, holding that an independent third party's dissemination may be advertising, the aim of the message being decisive. In MSD Sharp the Court held that Art. 88(1)(a) of the Directive does not prohibit a pharmaceutical company from placing on a website information about prescription-only medicines that is accessible only to a person who seeks it out, where the dissemination consists solely in the faithful reproduction of the packaging, in accordance with Art. 62 of the Directive, and in the literal, complete reproduction of the approved leaflet or summary of product characteristics; the same material, once selected or rewritten by the manufacturer and explicable only by an advertising purpose, is prohibited, and whether the activities at issue constituted advertising at all was left to the referring court.8Case C-316/09, on when a faithful website reproduction of approved product information stays outside the advertising prohibition. And in EUROAPTIEKA the Grand Chamber held that information encouraging the purchase of medicines by reference to price, by announcing a special sale, or by indicating that they are sold together with other products, is advertising even where it refers not to a specific medicine but to unspecified medicines.9Case C-530/20, holding that a message may be advertising even where it names no specific medicinal product.
A United States promotional file answers whether the product was named. Swiss and European law ask whether the message was designed to promote, and design is a question the marketing plan has already answered.
Read together, these authorities look like a workable test, and for a US team the reading is reassuring: keep the site pull rather than push, reproduce approved text verbatim, name no product. Applied to an actual launch, the reassurance dissolves. The disease-awareness asset is commissioned by the same brand team, on the same media plan, in the same quarter, through the same agency, and carries the same visual identity as the branded campaign that follows it. Whether that constitutes an indirect reference is a question about purpose. Purpose is documented, and it is documented in the campaign brief. The unbranded campaign therefore offers no safe harbor, because the evidence of its purpose already exists inside the company.
3. Gifts, Hospitality, and Samples: The Numbers Are Not in the Statute
Art. 94 of the Directive prohibits gifts, pecuniary advantages and benefits in kind from being supplied, offered or promised to prescribers or suppliers in the course of promotion, unless they are inexpensive and relevant to the practice of medicine or pharmacy. Hospitality at promotional events must always be strictly limited to the main purpose of the event, and Art. 95 Directive 2001/83/EC permits hospitality at events held for purely professional and scientific purposes only where it is strictly limited to the main scientific objective of the event. In both cases it must not be extended to persons other than healthcare professionals.2 The Directive never says what "inexpensive" means. On samples, Art. 96 Directive 2001/83/EC permits supply on an exceptional basis only to persons qualified to prescribe, against a written, signed and dated request, in a presentation no larger than the smallest on the market, marked as a free medical sample not for sale, accompanied by the summary of product characteristics and subject to an adequate system of control. The yearly number of samples, the provision says, "shall be limited." It states no number.2
The number exists. It is simply not in the Directive. The EFPIA Code of Practice supplies what the legislature withheld, treating it as a reasonable interpretation that each professional should receive no more than four samples of a particular medicine per year, for two years after first requesting them. The meal threshold is likewise absent from European legislation and present in the industry code, which requires each national member association to fix a monetary threshold in its own national code, and which resolves conflicts through a host-country principle under which the threshold of the country where the event takes place prevails.10The EFPIA Code of Practice, the self-regulatory instrument that supplies the sample ceiling and delegates meal thresholds to national codes. A US company preparing a European launch therefore discovers, usually late, that the numbers that govern European promotion in practice are not in the instrument it has been reading.
The Swiss Inversion
Switzerland inverts the arrangement. There the numbers sit in the ordinance. Advantages of modest value are permissible only up to CHF 300 per professional per year, and only where they bear on medical or pharmaceutical practice. Support for attendance at a training event is permissible only where it has been agreed in writing and where the participating professional, or the organization employing that professional, bears a self-contribution of at least one third of the costs for a continuing-education event (Fortbildung) and at least one fifth for a further-training event (Weiterbildung, the postgraduate training toward a specialist title), those costs including registration fees, travel, accommodation, meals and the minor side-program offerings the ordinance treats as subordinate. The ordinance dispenses with that contribution only where the professional renders an equivalent counter-performance under Art. 7 VITH during the event, or where the event requires no overnight stay on site and, leaving aside any meal following its technical part, lasts no more than half a working day. The self-contribution may not be refunded in whole or in part, and the travel, accommodation and meal costs of accompanying persons may not be met, even where the accompanying person is a professional in their own right.11The VITH (SR 812.214.31), the Swiss integrity and transparency ordinance implementing Art. 55 HMG and Art. 56 HMG.
Compensation for services is permitted, and here the drafting repays attention. Art. 7 VITH requires a written agreement recording the nature and extent of both the counter-performance and the compensation, and requires the compensation to stand in reasonable proportion to what was received; only meals up to CHF 100 taken within a professional discussion escape the written-agreement requirement. The same article lists what may be compensated, and it admits participation in advisory boards, workshops and market research only insofar as no advertising purpose exists.11
The American speaker bureau fails on that final qualification, and it fails on a test that a US compliance officer will not be applying. The Office of Inspector General's special fraud alert of November 2020 describes the suspect features of a US speaker program in the vocabulary of intent: alcohol, expensive meals, venues not conducive to education, repeat attendance by the same prescribers, speaker selection by the sales function.12US Anti-Kickback Statute, the Sunshine Act reporting regime, and the 2020 OIG special fraud alert on speaker programs. The Swiss provision does not ask about intent. It asks whether an advertising purpose exists, and where one does, the engagement is not an equivalent counter-performance at all. The payment then falls outside the Art. 55 HMG exception and becomes an undue advantage.
The consequence is graded in a way a US team will not anticipate. An intentional breach of the advertising provisions is punished under Art. 87 HMG by a fine of up to CHF 50,000, rising to a monetary penalty where the person acts on a commercial scale, while a negligent breach draws a fine of up to CHF 20,000. An intentional breach of the Art. 55 HMG integrity prohibition is not a contravention, the class of offense punished only by a fine: under Art. 86 HMG it carries a custodial sentence of up to three years or a monetary penalty.3 In Germany, a separate criminal statute covers the same conduct: since 4 June 2016, § 299a and § 299b of the German StGB have punished corruption in the healthcare sector with imprisonment of up to three years or a fine, and § 300 of the German StGB raises the range to imprisonment of three months to five years in an especially serious case, which as a rule exists where the advantage is of great magnitude or the offender acts on a commercial scale or as a member of a gang formed to commit such offenses repeatedly.13German HWG and StGB provisions, and the Austrian AMG, governing advertising and healthcare corruption in the two neighboring markets. The American analogue, the Anti-Kickback Statute, is itself a felony carrying up to ten years, so a US team will expect criminal penalties. In Switzerland, however, the line between a fine and a custodial offense runs between the advertising rules and the integrity rules, and a single hospitality decision can sit on either side of it.12
4. The Password Wall, Patient Influencers, and the Like Button
Art. 5a AWV states that professional advertising may not be made publicly accessible on the internet, that it must be furnished with a suitable technical and password-protected access restriction, and that it may be made available only to the prescribers and dispensers the ordinance identifies.4 The requirement is a password, not a declaration. The self-attestation checkbox that gates a US professional portal, the one that asks a visitor to certify that they are a healthcare professional, is not an access restriction within the meaning of that provision. A congress microsite without a login, a medical-information page indexed by search engines, a post addressed to specialists on a professional network: each is publicly accessible, and each is professional advertising if its purpose is promotional.
The like button is a sharper illustration. Swissmedic's published position is that advertising of medicines on social media is impermissible where the like, share and comment functions are activated for the post, because those functions allow the medicine to be rated, endorsed and furnished with reports of experience.14Swissmedic guidance on advertising in social media, and its January 2025 communication reporting 2023 advertising enforcement figures. The prohibition is anchored in Art. 22 AWV, whose bar on public-advertising elements forbids advertising that mentions or refers to scientific publications, studies, expert opinions, testimonials or recommendations by scientists, by persons working in healthcare, by well-known personalities or by medical-pharmaceutical laypersons.4 Unlawfulness therefore attaches not to the copy, which the compliance function reviews line by line, but to a platform setting, which it typically never sees.
Patient influencers make the problem worse. Swissmedic treats the advertising rules as binding every actor who advertises medicines to the public, expressly including influencers and media professionals.14 An influencer program leaves the company responsible and adds a second addressee of the same prohibition, in a channel whose defining features are the ones the ordinance forbids. Nor is the rest of the funnel safe: Art. 21 AWV separately makes unlawful, in public advertising, any invitation to contact the marketing authorization holder and the running of competitions, disapplying both only for medicines in dispensing category E, which anyone may dispense without expert advice.4 The "learn more" call to action and the patient sweepstake are each independently impermissible, and in Gintec the Court held that a prize draw announced on the internet is prohibited where it encourages the irrational use of the medicine and leads to its direct distribution to the public and to the presentation of free samples.5
What none of this resolves is the geography. Whether a campaign geo-targeted away from Switzerland, yet reachable from Basel by anyone who types the address, has been made publicly accessible within the meaning of Art. 5a AWV is not answered by the text. MSD Sharp indicates that a website which a user must actively seek out may be information rather than advertising, but a social feed is delivered rather than sought, and the distinction the Court drew between material that is pushed and material that is pulled was drawn before feeds were assembled by algorithm.8
5. Enforcement and the Ten-Year Retention Duty
The Office of Prescription Drug Promotion polices American promotion through untitled letters and warning letters. In practice it imposes no civil monetary penalty and holds no independent litigating authority; financial consequence arrives through the Department of Justice, generally under the False Claims Act and generally paired with kickback theories. Promotional pieces reach the agency at the time of their first dissemination, not before it.1 The US risk model is accordingly calibrated on two things a compliance committee understands: a letter, and a settlement.
Swissmedic supervises directly, and the supervision is neither remote nor rare. Any person or organization may report a suspected breach of the advertising provisions, and Swissmedic pursues suspected breaches on its own initiative.4 In the 2023 reporting year, according to the agency's communication of 16 January 2025, it handled 80 advertising cases, opened administrative proceedings in 27 of them and initiated criminal proceedings in 5; its monitoring extends across print, radio and television, online media and social-media platforms.14
The sanction with no American analogue is prior vetting of advertising. Art. 23 AWV empowers Swissmedic to require a marketing authorization holder that has seriously or repeatedly breached the advertising provisions to submit, for an appropriate period, every draft of its planned advertising for prior examination and approval.4 Art. 97 of the Directive likewise permits, without requiring, Member States to base their monitoring of advertising on a system of prior vetting.2 A measure that converts a company's entire promotional output into a pre-clearance queue for an indeterminate period is a commercial problem before it is a legal one, and a risk model that prices legal risk only in dollars will not see it.
The transparency divergence has a similar shape. Art. 56 HMG requires discounts and rebates granted on the purchase of therapeutic products to be shown in the receipts, invoices and business books of both the selling and the purchasing party, and disclosed to the competent authorities on request; the VITH directs that disclosure to the BAG.3 The duty does not stop at disclosure. Whoever manufactures or distributes the products covered must designate a person to furnish the BAG with documents and information on request, must retain every agreement concluded with professionals and organizations for ten years after its last use, and must maintain a register of all professionals and organizations that have received permissible advantages.11 Open Payments differs in shape more than in stringency. The American company reports its transfers of value each year, and a searchable federal database makes them public. The Swiss company publishes nothing, and must instead be able to produce, a decade after the fact, the written agreement behind an advisory-board payment made in the launch quarter.12
All of this rests on an instrument scheduled for repeal. Directive 2001/83/EC is to be replaced by the EU Pharma Package, but at the date of publication the Council's final compromise texts, confirmed on 6 March 2026, had not been adopted, so Title VIII still governs advertising.15The Council's final compromise text for the recast Directive, which will repeal Directive 2001/83/EC once adopted. The self-regulatory codes that supply the Directive's missing numbers are rules of the industry, not legislation. Art. 97 of the Directive preserves voluntary self-regulatory control as an addition to the judicial and administrative routes rather than a substitute for them, and a member company is bound by the relevant national code of each European country in which it operates, whether directly or through a subsidiary.210
6. Strategic Considerations for US Pharma Companies Launching in Europe
The frameworks do not answer the questions that decide a launch. Whether an unbranded disease-awareness asset carries a reference that is indirect within the meaning of Art. 86 of the Directive cannot be resolved by inspecting the asset. It is resolved by the campaign brief, the media plan and the agency scope of work, documents that sit with the brand team rather than with legal, and that were written to set out the promotional intent the European test is looking for. Whether those documents would survive an assessment of purpose is a question only the company can answer, and answering it means reading them against a standard they were never written to satisfy.
Access to the professional portal raises a related problem. Where a global professional portal is operated by a US parent and localized by a Swiss affiliate, which entity has made the professional advertising publicly accessible, and does a single-sign-on gate inherited from the parent's identity provider amount to the password-protected technical restriction that Art. 5a AWV demands? The provision speaks to a state of affairs rather than to a controller. Whether the affiliate may rely on the parent's access controls, and whether the parent has taken on a Swiss regulatory risk it has never modeled, are questions of fact about system design that no compliance function will have documented as legal positions.
A coordination gap opens where the two frameworks are read by different people. Regulatory affairs reads Art. 87 of the Directive and the Swiss requirement that claims track the approved product information. Medical affairs reads the advisory-board and market-research permissions of Art. 7 VITH and recognizes a familiar structure. Neither is likely to notice that the Swiss permission is qualified by the absence of an advertising purpose, or that an advisory board convened in the launch quarter, briefed on positioning and attended by the commercial team, may not have that absence available to it. The agreement will have been signed. The purpose will have been recorded somewhere else.
A position formed against the codes and guidance of 2026 must survive a ten-year retention obligation and a Directive with a scheduled successor. The ordinance does not say whether an agreement concluded in 2026 by a US parent with a Swiss professional, drafted in English and governed by New York law, is an agreement concluded within the meaning of the ordinance, and so one that must be kept for ten years after its last use. The answer turns on which entity contracted, and why, and whether anyone recorded the reason.
Nor do the consequences stay in Europe. An administrative measure that places a company's promotional output under prior examination, or a criminal proceeding under Art. 86 HMG, may become a material event for United States disclosure purposes long before any fine is assessed, and standard American directors-and-officers policies frequently sub-limit or exclude foreign regulatory actions. Whether the company's own risk register records the Swiss integrity provisions as a criminal matter rather than a promotional one determines whether that possibility was ever priced.